NewsRelease
ResearchArticle Cites HemogloBind™ in Diabetic Complications Study
MONMOUTHJUNCTION, NJ, May23, 2018-- Biotech Support Group reports on a recent research articledescribing the describingthe simplicity and efficiency of their hemoglobin depletiontechnology for improving Western blot analysis from whole blood. Thecitation is:
Pácal,Lukáš, et al. "DeleteriousEffect of Advanced CKD on Glyoxalase System Activity not Limited toDiabetes Aetiology."InternationalJournal of Molecular Sciences19.5 (2018): 1517.
Theauthors studied Methylglyoxal production known to increase indiabetic patients. Methylglyoxal is efficiently detoxified by enzymeglyoxalase 1 (GLO1). The aim was to study the effect of diabetic andchronic kidney disease milieu on (a) GLO1 gene expression inperipheral blood mononuclear cells; (b) GLO1 protein levels in wholeblood; and (c) GLO1 activity in RBCs in vivo in diabetic vs.non-diabetic subjects with normal or slightly reduced vs.considerably reduced renal function (CKD1-2 vs. CKD3-4). Toevaluate the GLO1 protein levels in wholeblood by Western blot, the article states “For proteinisolation, whole blood aliquots were lysed with water and haemoglobinwas removed using HemogloBind™ (Biotech Support Group, MonmouthJunction, NJ, USA) according to the manufacturer’s instructions…”. The article concludes that chronic kidney disease in advancedstages has prevailing and suppressive effects compared tohyperglycaemia. Chronic kidney disease decreases GLO1 gene expressionand protein levels (together with diabetes) without concomitantchanges of GLO1 activity.
“Thelarge amount of hemoglobin in whole blood presents a specialchallenge for quantitative Western blot analysis. Here is anotherarticle demonstrating that HemogloBind™ can reduce the interferenceassociated with large concentrations of hemoglobin, withoutcompromising the recovery and analysis of the protein of interest.”states Swapan Roy, Ph.D., President and Founder of Biotech SupportGroup.
Formore information on HemogloBind™, visit:
http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ for lipidadsorption, HemogloBind™ and HemoVoid™ for hemoglobin removal,and NuGel™ for functional proteomics. From these innovations, thecompany has acquired knowledgebase and biomarker intellectualproperty assets that support discoveries of protein markers fromblood, with special emphasis on early detection and personalizedmedical decisions for cancer patients. For more information, gotohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866,[email protected]